Sirbal to Receive Its Seventh Allowable US Patent

SAN FRANCISCO--()--Sirbal Ltd., a pharmaceutical company specializing in developing herbal medicinal and cosmetic products based on traditional Chinese medicine, announced today that it has received its seventh allowable US patent for its botanical based extract SIRB-001, its target illnesses application and ingredients.

“We believe that this tightly knit intellectual property protection further adds to the commercialization value of SIRB-001, on top of the already clinically proven efficacy and safety.”

The target illnesses cover the panoply of inflammatory skin diseases including psoriasis, atopic dermatitis, seborrhea and more. The granted and allowed patents describe medicinal dosage compositions and delivery methods, as well as multiple dose treatment regimens and preparation methods. The dosage compositions include multi-herbal extracts as well as molecular active ingredients. The described delivery methods include topical, subcutaneous, oral and/or intravenous.

In addition to the extensive coverage of dermatological, autoimmune and inflammatory diseases, the patent portfolio also address the use of SIRB-001 for oncological treatments targeting solid cancers such as melanoma, breast cancer, prostate cancer and colon cancer and hematological such as AML and CLL.

“These patents are part of an extensive patent strategy of more than 50 applications filed and prosecuted in the EPO, USPTO, JPO as well as other National offices,” said Nadav Shraibom, Sirbal’s CEO. “We believe that this tightly knit intellectual property protection further adds to the commercialization value of SIRB-001, on top of the already clinically proven efficacy and safety.”

About Sirbal

Sirbal Ltd. was founded by Mr. Nadav Shraibom, a Chinese Herbal Medicine Clinician, with Messrs. Tal Dilian and Eran Steinberg as co-founders. Its mission is to provide safe and efficient treatments for inflammatory diseases. Its first products based on a multi-herbal botanical extract, SIRB-001, clinically establishes clear efficacy and safety in topical care of the skin prone to multiple dermatological indications such as psoriasis, atopic dermatitis and seborrhea. For additional background information, including all granted and published patent applications and grants, please refer to http://www.sirbal.com/background.

Contact for Commercialization and Partnering Opportunities:

Franck Brinkhaus, PhD
Biotech Alliances International
(650) 868-8511 / franck.brinkhaus@biotech-alliances.com

Contacts

KMA & Company
Cassie Arnold, 408-621-0700
cassie@KMAandCo.com

Recent Stories

RSS feed for Sirbal Ltd.